- ADVERTISEMENT FEATURE Advertiser retains sole responsibility for the content of this article
Therapeutic genome editing
Precision BioSciences is harnessing its next-generation genome editing platform, ARCUS, to develop a pipeline of cell-based immunotherapies for cancer and autoimmune disease, as well as gene therapies for rare genetic disorders. The company is looking for uniquely suited partners to aid in these efforts.